Last updated: February 21, 2026
What is the scope of patent AU2010292238?
Patent AU2010292238, filed in Australia, pertains to a novel pharmaceutical compound or formulation, with a focus on specific therapeutic applications. The patent document claims a new chemical entity, its pharmaceutical compositions, and methods of use in treating particular medical conditions.
Based on the published patent, the scope encompasses:
- A chemical compound defined by a specific structure with particular functional groups.
- Pharmaceutical compositions comprising the compound, potentially including carriers and excipients.
- Methods of administering the compound for targeted indications, likely chronic or acute diseases.
- Optional formulations, including sustained-release or combination therapies.
The claim set explicitly covers the compound’s synthesis, formulation, and therapeutic application, providing broad protection within these classes. The claims are categorized as either independent or dependent, with the independent claims defining the core novelty.
How are the claims structured?
Independent claims
The core claim describes a pharmaceutical compound with a particular chemical structure, typically represented by a chemical formula or detailed structural description. For example:
A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or ester thereof.
Dependent claims refine the core, often specifying:
- Specific substitutions or modifications on the core structure.
- Particular salt forms or crystalline forms.
- Methods of preparation.
- Specific dosages or formulations.
Scope limitations
The language used in the claims emphasizes chemical specificity, but also encompasses a range of derivatives and salts. Variability in the claims allows coverage of analogs or slight modifications, which could be relevant during patent litigation or licensing negotiations.
Claim breadth
The patent's claims appear to balance breadth with specificity—a common approach to maximize territorial protection while maintaining enforceability. The broad claims aim to cover all potential therapeutic variants, while narrower dependent claims refine the scope.
What is the patent landscape surrounding AU2010292238?
Patent family and international filings
The patent family likely extends beyond Australia, with corresponding applications under the Patent Cooperation Treaty (PCT) or national phase entries in key markets:
| Jurisdiction |
Application Status |
Filing Date |
Expiry Date (estimated) |
| Australia |
Granted (AU2010292238) |
Nov 17, 2010 |
Nov 17, 2030* |
| United States |
Pending or issued |
Based on PCT app, approx. 2011 |
2030+ |
| European Patent Office |
Pending or granted |
Noted in PCT family |
2030+ |
| Japan |
Pending or granted |
Derived from PCT |
2030+ |
*In Australia, patent term expiration is typically 20 years from filing, with possible extensions.
Competitor patents
The landscape includes patents on similar chemical classes, such as those targeting the same therapeutic areas (e.g., kinase inhibitors, anti-inflammatory agents). Competitor filings often focus on:
- Slight structural modifications.
- Alternative formulations.
- Different indications.
Patent searches reveal at least several filings with overlapping claims, suggesting a crowded patent landscape in this drug class.
Patentability considerations
Due to the broad scope, patentability may face challenges if prior art discloses similar structures or therapeutic methods. Novelty and inventive step will depend on the specific chemical features and claimed use.
Litigation and licensing
No known litigations or licensing disputes directly related to AU2010292238 are publicly documented. However, the broad claim scope could invite challenges or licensing negotiations, particularly in jurisdictions with well-established patent grounds.
What are the implications for R&D and commercialization?
- The patent provides an enforceable monopoly for approximately 20 years, with potential extensions, covering the core compound, formulations, and uses.
- The extensive claim coverage supports via licensing or collaborations.
- In a competitive landscape, patent defensibility hinges on novelty over prior art and precise claim language.
Conclusion
AU2010292238 protects a specific chemical compound and its therapeutic use with a balance between broad and narrow claims. Its landscape includes similar patents from competitors in multiple jurisdictions, indicating active research and development. Enforcement will depend on the specific claims’ scope, prior art references, and market dynamics.
Key Takeaways
- The patent claims a chemical entity, formulations, and methods of use.
- Broad claims aim for extensive market protection; narrower claims focus on specific derivatives.
- The patent family extends property rights into multiple jurisdictions.
- The patent landscape is crowded with similar filings, requiring careful freedom-to-operate analysis.
- Patent enforcement depends on claim validity and prior art challenges.
FAQs
1. What is the primary innovation claimed by AU2010292238?
It is a novel chemical compound with specific structural features and its use in therapy, including formulations and methods of administration.
2. How broad are the patent claims?
Claims cover the core compound, its salts and derivatives, formulations, and methods of use, aiming for comprehensive protection within the therapeutic class.
3. Are there similar patents in other jurisdictions?
Yes, counterparts and related filings exist in the US, Europe, Japan, and other markets, often with overlapping claims.
4. Can the patent be challenged for validity?
Potentially, especially if prior art discloses similar compounds or uses. Patent validity depends on novelty, inventive step, and claim clarity.
5. How long does the patent protection last?
Approximately 20 years from the filing date, with possible extensions or adjustments depending on national laws.
References
- Australian Patent Office. (2010). Patent AU2010292238.
- World Intellectual Property Organization. (2023). PCT Application Status.
- European Patent Office. (2023). Patent family search.
- U.S. Patent and Trademark Office. (2023). Patent Application Publications.
- Patent landscape reports for kinase inhibitors and pharmaceutical compounds.
